{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:35:54Z","timestamp":1791182154414,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.cbpa.2007.05.035","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T07:10:46Z","timestamp":1185261046000},"page":"412-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Gaucher disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Terry D","family":"Butters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2007.05.035_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2004.05293.x","article-title":"Lysosomal storage disorders","volume":"128","author":"Vellodi","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00126839-200607060-00003","article-title":"A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders","volume":"7","author":"Pastores","year":"2006","journal-title":"Drugs R D"},{"key":"10.1016\/j.cbpa.2007.05.035_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ymgme.2006.01.010","article-title":"Lysosomal storage diseases: natural history and ethical and economic aspects","volume":"88","author":"Beutler","year":"2006","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2007.05.035_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cbpa.2007.05.035_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's Disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cbpa.2007.05.035_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cbpa.2007.05.035_bib8","first-page":"703","article-title":"Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease","volume":"91","author":"Giraldo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.cbpa.2007.05.035_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","article-title":"An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment","volume":"27","author":"Pastores","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.cbpa.2007.05.035_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcmd.2007.02.008","article-title":"A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated (R) human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease","volume":"39","author":"Zimran","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2007.05.035_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2174\/1389200013338414","article-title":"Agents for the treatment of glycosphingolipid storage disorders","volume":"2","author":"Abe","year":"2001","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.cbpa.2007.05.035_bib12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.tetasy.2005.03.015","article-title":"Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease","volume":"16","author":"Boucheron","year":"2005","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1016\/j.cbpa.2007.05.035_bib13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1021\/jo061280p","article-title":"Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man","volume":"72","author":"Wennekes","year":"2007","journal-title":"J Org Chem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/14656566.8.4.427","article-title":"Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders","volume":"8","author":"Butters","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cbpa.2007.05.035_bib15","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.cbpa.2007.05.035_bib16","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00018-005-5437-0","article-title":"Therapeutic strategies to ameliorate lysosomal storage disorders\u2014a focus on Gaucher disease","volume":"63","author":"Sawkar","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cbpa.2007.05.035_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2006-03-010801","article-title":"Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease","volume":"108","author":"Zimran","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cbpa.2007.05.035_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2007.05.035_bib19","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2007.05.035_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1042\/BJ20031822","article-title":"Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis","volume":"381","author":"Mellor","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.cbpa.2007.05.035_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/bj20020466","article-title":"Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins","volume":"366","author":"Mellor","year":"2002","journal-title":"Biochem J"},{"key":"10.1016\/j.cbpa.2007.05.035_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10545-006-0272-5","article-title":"Substrate reduction therapy of glycosphingolipid storage disorders","volume":"29","author":"Aerts","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cbpa.2007.05.035_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2007.05.035_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1365-2141.2004.05351.x","article-title":"Gaucher disease: pathological mechanisms and modern management","volume":"129","author":"Jmoudiak","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1146\/annurev.biochem.73.011303.073752","article-title":"Roles of N-linked glycans in the endoplasmic reticulum","volume":"73","author":"Helenius","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00018-004-4037-8","article-title":"Role of N-linked polymannose oligosaccharides in targeting glycoproteins for endoplasmic reticulum-associated degradation","volume":"61","author":"Spiro","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.cbpa.2007.05.035_bib27","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1091\/mbc.12.6.1711","article-title":"A novel quality control compartment derived from the endoplasmic reticulum","volume":"12","author":"Kamhi-Nesher","year":"2001","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.cbpa.2007.05.035_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1083\/jcb.200507057","article-title":"Derlin-2 and Derlin-3 are regulated by the mammalian unfolded protein response and are required for ER-associated degradation","volume":"172","author":"Oda","year":"2006","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib29","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1073\/pnas.0700154104","article-title":"EDEM1 reveals a quality control vesicular transport pathway out of the endoplasmic reticulum not involving the COPII exit sites","volume":"104","author":"Zuber","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2007.05.035_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1096\/fj.01-0889rev","article-title":"Cytoplasmic peptide: N-glycanase (PNGase) in eukaryotic cells: occurrence, primary structure, and potential functions","volume":"16","author":"Suzuki","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.cbpa.2007.05.035_bib31","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.biocel.2005.05.008","article-title":"Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease","volume":"37","author":"Schmitz","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cbpa.2007.05.035_bib33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib34_1","doi-asserted-by":"crossref","first-page":"23815","DOI":"10.1074\/jbc.M502799200","article-title":"X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease","volume":"280","author":"Premkumar","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib35_1","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1074\/jbc.M511110200","article-title":"Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations","volume":"281","author":"Liou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib36_1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib37","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.cbpa.2007.05.035_bib38","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/cb600187q","article-title":"Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants","volume":"1","author":"Sawkar","year":"2006","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib39","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cbpa.2007.05.035_bib40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep"},{"key":"10.1016\/j.cbpa.2007.05.035_bib41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/cbic.200600217","article-title":"Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease","volume":"7","author":"Compain","year":"2006","journal-title":"Chembiochem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib42_1","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1002\/anie.200502662","article-title":"Rational design and synthesis of highly potent beta-glucocerebrosidase inhibitors","volume":"44","author":"Zhu","year":"2005","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.cbpa.2007.05.035_bib43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/jm060677i","article-title":"Isofagomine- and 2,5-anhydro-2,5-imino-d-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention","volume":"50","author":"Yu","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib44","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"Alpha-1-C-octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2007.05.035_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2007.02.003","article-title":"Enzyme enhancement activity of N-octyl-beta-valienamine on beta-glucosidase mutants associated with Gaucher disease","author":"Lei","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cbpa.2007.05.035_bib46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.cbpa.2007.05.035_bib47","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2006.09.008","article-title":"Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease","volume":"90","author":"Sinclair","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cbpa.2007.05.035_bib48","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bcp.2006.12.015","article-title":"Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase","volume":"73","author":"Steet","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cbpa.2007.05.035_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chembiol.2006.12.006","article-title":"High-throughput screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones","volume":"14","author":"Tropak","year":"2007","journal-title":"Chem Biol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593107000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593107000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:18:23Z","timestamp":1761272303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593107000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1367593107000798"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2007.05.035","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2007.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}